Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma

Angiogenesis

Volumn 16, Issue 4, 2013, Pages 963-973

  De Luisi, Annunziata ^a   Binetti, Laura ^a   Ria, Roberto ^a   Ruggieri, Simona ^a,c   Berardi, Simona ^a   Catacchio, Ivana ^a   Racanelli, Vito ^a   Pavone, Vincenzo ^b   Rossini, Bernardo ^b   Vacca, Angelo ^a   Ribatti, Domenico ^c,d  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b Hematology Unit   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Angiogenesis; Erythropoietin; Macrophages; Multiple myeloma; Tumor growth

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ANEMIA; ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL MOTILITY; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION;

AGED; ANDROSTADIENES; ANGIOGENIC PROTEINS; ANIMALS; BONE MARROW; BONE MARROW CELLS; CAPILLARIES; CELL MOVEMENT; CELLS, CULTURED; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; CHROMONES; CULTURE MEDIA, CONDITIONED; CYTOKINES; ERYTHROPOIETIN; HUMANS; MACROPHAGES; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MORPHOLINES; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884809521     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-013-9369-2     Document Type: Article

References (38)

1. Vacca A, Ribatti D, Roncali L, et al. (1994) Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87(3):503-508
2. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A (2007) The history of the angiogenic switch concept. Leukemia 21(1):44-52
3. Vacca A, Ribatti D (2006) Bone marrow angiogenesis in multiple myeloma. Leukemia 20(2):193-199
4. Ribatti D, Nico B, Vacca A (2006) Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 25(31):4257-4266
5. Scavelli C, Nico B, Cirulli T, et al. (2008) Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 27(5):663-674
6. Ribatti D (2012) Angiogenic effects of erythropoietin. Int Rev Cell Mol Biol 299:199-234
7. Lifshitz L, Tabak G, Gassmann M, Mittelman M, Neumann D (2010) Macrophages as a novel target for erythropoietin. Haematologica 95(11):1823-1831
8. Vacca A, Ria R, Semeraro F, et al. (2003) Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 102(9):3340-3348
9. Moschetta M, Di Pietro G, Ria R, et al. (2010) Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 46(2):420-429
10. De Luisi A, Ferrucci A, Coluccia AML, et al. (2011) Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res 17(7):1935-1946
11. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25(4):402-408
12. Ribatti D, Nico B, Vacca A, Presta M (2006) The gelatin sponge-chorioallantoic membrane assay. Nat Protoc 1(1):85-91
13. Elliott S, Sinclair AM (2012) The effect of erythropoietin on normal and neoplastic cells. Biologics 6:163-189
14. Ribatti D, Presta M, Vacca A, et al. (1999) Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93(8):2627-2636
15. Perelman N, Selvaraj SK, Batra S, et al. (2003) Placenta growth factor activates monocytes and correlates with sickle disease severity. Blood 102(4):1506-1514
16. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H (2008) Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 10(9):932-939
17. Blackwell KL, Kirkpatrick JP, Snyder SA, et al. (2003) Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res 63(19):6162-6165
18. Hardee ME, Cao Y, Fu P, et al. (2007) Erythropietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2(6):e549
19. Xue Y, Lim S, Yang Y, et al. (2011) PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med 18(1):100-110
20. Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R, Vacca A (2003) Erytropoietin is an angiogenic factor in gastric carcinoma. Histopathology 42(3):246-250
21. Ribatti D, Marzullo A, Gentile A, et al. (2007) Erytropoietin/ erytropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 50(5):591-596
22. Ribatti D, Poliani PL, Longo V, Mangieri D, Nico B, Vacca A (2007) Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human neuroblastoma. Histopathology 50(5):636-641
23. Ribatti D, Nico B, Perra MT, et al. (2010) Erytropoietin is involved in angiogenesis in human primary melanoma. Int J Exp Pathol 91(6):495-499
24. Nico B, Annese T, Guidolin D, Finato N, Crivellato E, Ribatti D (2011) Epo is involved in angiogenesis in human glioma. J Neurooncol 102(1):51-58
25. Yang J, Xiao Z, Li T, Gu X, Fan B (2012) Erytropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis. Int J Oncol 40(4):1230-1237
26. Ribatti D, Crivellato E, Nico B, Guidolin D, Gassmann M, Djonov V (2009) Mast cells and macrophages in duodenal mucosa of mice overexpressing erythropoietin. J Anat 215(5):548-554
27. Bogdanova A, Mihov D, Lutz H, Saam B, Gassmann M, Vogel J (2007) Enhanced erythro-phagocytosis in polycythemic mice overexpressing erythropoietin. Blood 110(2):762-769
28. Haroon ZA, Amin K, Jiang X, Arcasoy MO (2003) A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 163(3):993-1000
29. Olujihungle A, Handa S, Holmes J (1997) Does erythropoietin accelerate malignant transformation in multiple myeloma? Postgrad Med J 73(857):163-164
30. Bunworasate U, Arnouk H, Minderman H, et al. (2001) Erythopoietin- dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood 98(12):3492-3494
31. Mittelman M, Zeidman A, Fradin Z, Magazanik A, Lewinski UH, Cohen A (1997) Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol 98(4):204-210
32. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N (2001) Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 98(9):5181-5186
33. Prutchi-Sagiv S, Golishevsky N, Oster HS, et al. (2006) Erytropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? Br J Haematol 135(5):660-672
34. Katz O, Barzilay E, Skaat A, Herman A, Mittelman M, Neumann D (2005) Erytropoietin induced tumor mass reduction in murine lymphoproliferative models. Acta Haematol 114(3):177-179
35. Katz O, Gil L, Lifshitz L, et al. (2007) Erytropoietin enhances immune responses in mice. Eur J Immunol 37(6):1584-1593
36. Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4(8):459-460
37. Powles T, Shamash J, Liu W (2004) Erytropoietin to treat anemia in patients with head and neck cancer. Lancet 363(9402):82
38. Cao Y (2013) Erytropoietin in cancer: a dilemma in risk therapy. Trends Endocrinol Metab 24(4):190-199